Futures & Options
Buy Or Sell
Savings & Investments
Banking & Financial Services
Tech, Media & Telecom
Aurobindo Pharma Receives US Regulator's Nod for Generic Drug
Drug firm Aurobindo Pharma has received approval from the US Food and Drug Administration (FDA) to manufacture and market generic Norethindrone Acetate tablets in the American market.
Press Trust of India
| Last Updated: January 11, 2016 14:28 (IST)
Press Trust of India
: Drug firm
has received approval from the US Food and Drug Administration (FDA) to manufacture and market generic Norethindrone Acetate tablets in the American market.
The company has received the final nod from the US health regulator to manufacture and market Norethindrone Acetate tablets in the strength of 5 mg, Aurobindo Pharma said in a statement.
"The approved product has an estimated market size of $24 million for the 12 months ending November 2015 according to IMS," it added.
The company's product is generic version of Duramed Pharmaceuticals' Aygestin tablets in the same strength, Aurobindo Pharma said.
"Norethindrone Acetate tablet is used in the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels and secondary amenorrhea," it added.
The company has a total of 230 abbreviated new drug application (ANDA) approvals (199 final approvals including 10 from Aurolife Pharma LLC and 31 tentative approvals) from FDA.
At 2:24 p.m., shares in
were trading 0.70 per cent lower at Rs 840.20 apiece on the BSE, whose benchmark Sensex index was down 0.04 per cent.
latest news on Business
, like us on
and follow us on
Story first published on
: January 11, 2016 14:21 (IST)
Expect Royalty To Suzuki In Rupee On All Models By 2025: Maruti
Pay Rs 1,500 Crore Or Face Jail: Top Court Warns Sahara's Subrata Roy
Kotak Mahindra Bank Q4 Net Profit Jumps 40%
When 'Excited' AirAsia Crew Was Ready To Fly To An Indian City
Rs 2,500 For 1-Hour Flight: PM Modi Launches Low-Cost UDAN Scheme
Rupee Gets Stronger, Rises To 21-Month High Against Dollar
Share this story on
7th Pay Commission: Allowance Report Submitted, Other Latest Developments
GAINERS / LOSERS
Can Indian IT Overcome H-1B Visa Hurdles?
Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2017. All rights reserved.